These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 39364394)
1. Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS-CoV-2 Omicron infection. Toh ZQ; Anderson J; Mazarakis N; Quah L; Nguyen J; Higgins RA; Do LAH; Ng YY; Jalali S; Neeland MR; McMinn A; Saffery R; McNab S; McVernon J; Marcato A; Burgner DP; Curtis N; Steer AC; Mulholland K; Pellicci DG; Crawford NW; Tosif S; Licciardi PV Clin Transl Immunology; 2024; 13(10):e70008. PubMed ID: 39364394 [TBL] [Abstract][Full Text] [Related]
2. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2024; 15():1420304. PubMed ID: 39267752 [TBL] [Abstract][Full Text] [Related]
3. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I Front Immunol; 2023; 14():1099246. PubMed ID: 36756112 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients. Chen Y; Zhao T; Chen L; Jiang G; Geng Y; Li W; Yin S; Tong X; Tao Y; Ni J; Lu Q; Ning M; Wu C mBio; 2024 Apr; 15(4):e0240723. PubMed ID: 38456703 [TBL] [Abstract][Full Text] [Related]
5. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study. Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735 [TBL] [Abstract][Full Text] [Related]
7. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study. Guo L; Zhang Q; Gu X; Ren L; Huang T; Li Y; Zhang H; Liu Y; Zhong J; Wang X; Chen L; Zhang Y; Li D; Fang M; Xu L; Li H; Wang Z; Li H; Bai T; Liu W; Peng Y; Dong T; Cao B; Wang J Lancet Microbe; 2024 Jan; 5(1):e24-e33. PubMed ID: 38048805 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults. Tunheim G; Fossum E; Robertson AH; Rø GØI; Chopra A; Vaage JT; Vikse EL; Kran AB; Magnus P; Trogstad L; Mjaaland S; Hungnes O; Lund-Johansen F BMC Infect Dis; 2024 Aug; 24(1):841. PubMed ID: 39164637 [TBL] [Abstract][Full Text] [Related]
9. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial. Poh XY; Lee IR; Tan CW; Chavatte JM; Fong SW; Goh YS; Rouers A; Wong N; Torres-Ruesta A; Mah SYY; Yeoh AYY; Gandhi M; Rahman N; Chin YQ; Lim JJ; Yoong TJK; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim DRX; Chia W; Renia L; Ren EC; Lin RTP; Lye DC; Wang LF; Ng LFP; Young BE EBioMedicine; 2024 Sep; 107():105275. PubMed ID: 39137572 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318 [TBL] [Abstract][Full Text] [Related]
11. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903 [TBL] [Abstract][Full Text] [Related]
12. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540 [TBL] [Abstract][Full Text] [Related]
13. Humoral Response Kinetics and Cross-Immunity in Hospitalized Patients with SARS-CoV-2 WT, Delta, or Omicron Infections: A Comparison between Vaccinated and Unvaccinated Cohorts. Kang H; Lee J; Jung J; Oh EJ Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140207 [TBL] [Abstract][Full Text] [Related]
14. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting. Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634 [TBL] [Abstract][Full Text] [Related]
15. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5. Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A Front Immunol; 2023; 14():1150667. PubMed ID: 37520539 [TBL] [Abstract][Full Text] [Related]
16. Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer. Chen C; Zhou X; Gao X; Pan R; He Q; Guo X; Yu S; Wang N; Zhao Q; Wang M; Xu Y; Han X Int J Cancer; 2024 Oct; 155(8):1409-1421. PubMed ID: 38837354 [TBL] [Abstract][Full Text] [Related]
17. Diverging humoral and cellular immune responses due to Omicron-a national study from the Faroe Islands. Petersen MS; Pérez-Alós L; Í Kongsstovu SK; Eliasen EH; Hansen CB; Larsen S; Hansen JL; Bayarri-Olmos R; Fjallsbak JP; Weihe P; Garred P Microbiol Spectr; 2023 Dec; 11(6):e0086523. PubMed ID: 37909772 [TBL] [Abstract][Full Text] [Related]
18. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study. Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774 [TBL] [Abstract][Full Text] [Related]
19. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals. Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure. Kang H; Jung J; Ko GY; Lee J; Oh EJ Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]